Bank of America Securities is betting big on a small biotech company called Immix Biopharma (Immix Biopharma (IMMX)). On Thursday, BofA initiated coverage with a Buy rating and a $27 price target, pointing to the company's lead drug candidate, NXC-201, as a potential game-changer for patients with AL amyloidosis.

AL amyloidosis is a nasty, rare disease. It's a plasma cell disorder where rogue cells in the bone marrow churn out misfolded antibody proteins—light chains—that clump together as amyloid deposits. These deposits slowly wreck organs like the heart and kidneys. There's no approved therapy for relapsed or refractory patients, which is where NXC-201 comes in.

BofA analyst Tazeen Ahmad laid out the bull case: "We view NXC-201 in r/r AL as a compelling opportunity given high CR rates and no approved therapies." The firm assumes a 2028 U.S. launch based on current timelines and gives the drug a 50% likelihood-of-success, which is pretty standard for this stage. On that basis, BofA models worldwide risk-adjusted peak sales of $963 million. Not bad for a company with a market cap under $300 million.

The data so far is eye-catching. In May, Immix reported a 95% complete response rate in its Phase 2 trial for relapsed/refractory AL amyloidosis. Nineteen of the first 20 patients hit a complete response within a year, and none have relapsed yet. The company plans to start a Phase 3 trial in newly diagnosed patients, with the next clinical update expected in September 2026. In January, the FDA granted Breakthrough Therapy Designation to NXC-201 based on the Phase 2 interim data from the NEXICART-2 trial.

But BofA isn't all sunshine and rainbows. The analyst flagged several risks that could trip up the stock. First, durability: will those high complete response rates hold up with longer follow-up? Second, safety: AL amyloidosis patients are often frail, with damaged organs. Even a modest uptick in side effects like cytokine release syndrome, neurotoxicity, or cardiac events could limit real-world adoption. Third, access: CAR-T therapies are complex to manufacture and administer. As demand for other CAR-Ts grows, manufacturing capacity and treatment center slots could constrain NXC-201's uptake. And fourth, competition: other BCMA-targeted CAR-Ts and bispecific antibodies are in development, which could eat into Immix's market.

Still, BofA thinks the positives outweigh the negatives. "However, we think NXC-201's strong efficacy and lack of treatment options support a favorable commercial setup for IMMX," the firm wrote on Thursday.

Immix shares were up 2.52% at $9.90 at the time of publication on Thursday. That's a long way from BofA's $27 target, but with a binary drug-development story, the path is rarely a straight line.